CVS Health (NYSE:CVS) Issues Quarterly Earnings Results

CVS Health (NYSE:CVS) posted its quarterly earnings results on Wednesday. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30, Zacks reports. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. CVS Health updated its FY 2025 guidance to 5.750-6.000 EPS.

CVS Health Price Performance

NYSE CVS traded up $8.18 during trading hours on Wednesday, reaching $63.18. 8,888,677 shares of the company’s stock were exchanged, compared to its average volume of 12,220,979. The firm has a fifty day moving average of $50.61 and a 200-day moving average of $55.92. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80. CVS Health has a one year low of $43.56 and a one year high of $80.75. The stock has a market cap of $79.50 billion, a PE ratio of 16.09, a price-to-earnings-growth ratio of 0.60 and a beta of 0.61.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.21%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is currently 67.51%.

Wall Street Analyst Weigh In

CVS has been the subject of several analyst reports. Wells Fargo & Company raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $60.00 to $66.00 in a research note on Monday, November 18th. Truist Financial reduced their price objective on CVS Health from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Mizuho cut their price objective on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research report on Tuesday, December 3rd. Finally, StockNews.com cut CVS Health from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $67.78.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.